Adverse health effects of indoor molds

Journal of Nutritional and Environmental Medicine

Volumn 14, Issue 3, 2004, Pages 261-274

  Curtis, Luke ^a   Lieberman, Allan ^b   Stark, Martha ^c   Rea, William ^d   Vetter, Marsha ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Ctr for Occup and Environ Health   (United States)

^c HARVARD UNIVERSITY   (United States)

^d Environmental Health Center   (United States)

^e Environmental Health Center   (United States)

Author keywords

Allergy; Alternaria; Aspergillus; Asthma; Cladosporium; Fungi; Indoor air quality; Lung hemorrhage; Mold; Mycotoxin; Neurotoxicity; Penicillium; Stachybotrys

Indexed keywords

MYCOTOXIN;

AIR QUALITY; ALTERNARIA; AMBIENT AIR; ASPERGILLUS; ASTHMA; CLADOSPORIUM; DIABETES MELLITUS; HEALTH HAZARD; HUMAN; INDOOR AIR POLLUTION; LUNG HEMORRHAGE; MEDLINE; MOULD; NEPHROTOXICITY; NEUROTOXICITY; PENICILLIUM; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; RHINOSINUSITIS; RISK ASSESSMENT; STACHYBOTRYS; WHEEZING;

ALTERNARIA; ASPERGILLUS; CLADOSPORIUM; FUNGI; PENICILLIUM; STACHYBOTRYS;

EID: 11844305600     PISSN: 13590847     EISSN: None     Source Type: Journal    
DOI: 10.1080/13590840400010318     Document Type: Review

References (171)

1. Umberger M. The start that upstaged the economy. Chicago Tribune, 13 January 2002, available at WL 2612028, database ALLNEWS.
2. Mold claims hit $4 billion in Texas, Insurance Journal, 27 May 2003 (http://insurancejournal.com).
3. The Canadian Task Force on the Periodic Health Examination. The Canadian Guide to Clinical Preventative Health Care. Ottawa: Supply and Services Canada, 1994.
4. Samson R, Hoekstra E, Frisvad J, Filtenborg O. Introduction to Food and Airborne Fungi. Utrecht: Centraalbureau voor Schimmelcultures, 2000.
5. Miller JD. Fungi as contaminants of indoor air. Atmos Environ 1992; 26A(12): 2162-72.
6. Presternon DR. Perceived moisture problems in Iowa homes. Technical note. Forest Products J 1991; 41(6): 47-48.
7. Platt S, Martin C, Hunt S, Lewis C. Damp housing, mould growth and symptomatic health state. Br Med J 1989; 298: 1673-8.
8. Brunekreef B, Dockery D, Speizer FE. Home dampness and respiratory morbidity in children. Am Rev Resp Dis 1989; 140: 1363-7.
9. Dales R, Zwanenburg H, Burnett R, Franklin C. Respiratory health effects of home dampness and molds among Canadian children. Am J Epidemiol 1991; 134(2): 196-203.
10. Etzel R. Indoor air pollutants in homes and schools. Pediatr Clin North Am 2001; 48(5): 1153-65.
11. Flannigan B, McCabe E, McGarry F. Allergic and toxigenic microorganisms in houses. J Appl Bacteriol 1991; 70: 61S-73S.
12. Dhillion M. Current status of mold immunotherapy. Ann Allergy 1991; 66: 385.
13. Curtis L, Ross M, Persky V et al. Bioaerosol concentrations in the Quad Cities 1 year after the 1993 Mississippi River floods. Indoor Built Environ 2000; 9: 35-43.
14. Shelton B, Kirkland K, Flanders WD, Morris G. Profiles of airborne fungi in buildings and outdoor environments in the United States. Appl Environ Microbiol 2002; 68(4): 1743-53.
15. Ren P, Jankun T, Leaderer B. Comparisons of seasonal fungal prevalence in indoor and outdoor air and in house dwellings in one Northeast American county. J Exposure Anal Environ Epidemiol 1999; 9: 560-8.
16. Pei-Chih W, Huey-Jen S, Chia-Yin L. Characteristics of indoor and outdoor airborne fungi at suburban and urban homes in two seasons. Sci Total Environ 2000; 253: 111-18.
17. Li CS, Kuo YM. Characteristics of airborne microfungi in subtropical homes. Sci Total Environ 1994; 155(3): 267-71.
18. Ebner E, Hasselwandter K, Frank A. Indoor and outdoor incidence of airborne fungal allergens at low and high alpine environments. Mycol Res 1992; 97: 117-24.
19. Solomon WR. A volumetric study of winter fungus prevalence in the air of midwestern homes. J Allergy Clin Immunol 1976; 57(1): 46-55.
20. Beaumont F, Kauffman HF, Sluiter HJ, DeVries K. A volumetric- aerobiological study of seasonal fungus prevalence inside and outside dwellings of asthmatic patients living in northeast Netherlands. Ann Allergy 1984; 53(6): 486-92.
21. Lieberman A. Explosion of mold cases in homes, workplaces and occupational medicine practices. Presented at the 21st Annual Symposium on Man and His Environment in Health and Disease, Dallas, Texas, 19-22 June 2003.
22. Dennis D. Chronic sinusitis: defective T-cells responding to superantigens, treated by reduction of fungi in the nose and air. Arch Environ Health 2003; 58(7): 433-41.
23. Rea WJ, Didriksen N, Simon TR, Pan Y, Fenyves EJ, Griffiths B. Effects of toxic exposure to molds and mycotoxins in building-related illnesses. Arch Environ Health 2003; 58(7): 399-405.
24. Kilburn KH. Indoor mold exposure associated with neurobehavioral and pulmonary impairment: a preliminary report. Arch Environ Health 2003; 58(7): 390-8.
25. Campbell A, Thrasher J, Madison R, Vojdani A, Gray M, Johnson A. Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds in water damaged buildings. Arch Environ Health 2003; 58(8): 464-78.
26. Kurup V, Shen HD, Vijay H. Immunobiology of fungal allergens. Int Arch Allergy Immunol 2002; 129: 181-8.
27. Gorny RL, Reponen T, Willeke K et al. Fungal fragments as indoor air contaminants. Appl Environ Microbiol 2002; 68: 3522-31.
28. Institute of Medicine. Clearing the Air. Asthma and Indoor Exposures. Institute of Medicine, 2000.
29. Korpi A, Kasanen JP, Kosma VM, Rylander R, Pasanen AL. Slight respiratory irritation but not inflammation in mice exposed to (1 > 3)-beta-D-glycan aerosols. Mediat Inflamm 2003; 12(3): 139-46.
30. Etzel R. Mycotoxins. J Am Med Assoc 2002; 287(4): 425-7.
31. Nielsen KF. Mycotoxin production by indoor molds. Fungal Genet Biol 2003; 39: 103-17.
32. Rylander R. Indoor air-related effects and airborne (1 > 3)-beta-D-glucan. Environ Health Perspect 1999; 107(Supplement 3): 501-3.
33. Wilkins K, Larsen K, Simkus M. Volatile metabolites from mold growth on building materials and synthetic media. Chemosphere 2000; 41(3): 437-46.
34. Bennett J, Klich M. Mycotoxins. Clin Microbiol Rev 2003; 16(3): 497-516.
35. Hardin B, Kelman B, Saxon A. ACOEM evidence base statement. Adverse health effects associated with molds in the indoor environment. J Occup Environ Med 2003; 45(5): 470-8.
36. Richard J, Plattner R, May J, Liska S. The occurrence of ochratoxin A in dust collected from a problem household. Mycopathologica 1999; 146(2): 99-103.
37. Smoragiewicz W, Cossette B, Boutard A, Krystyniak K. Trichothecene mycotoxins in the dust of ventilation systems in office buildings. Int Arch Occup Environ Health 1993; 65(2): 113-17.
38. Engelhart S, Loock A, Skutlarek D et al. Occurrence of toxigenic Aspergillus versicolor isolates and sterigmatocystin in carpet dust from damp indoor environments. Appl Environ Microbiol 2002; 68(8): 3886-90.
39. Iavacoli I, Brera C, Carelli G, Caputi R, Marinaccio A, Miraglia M. External and internal dose in subjects occupationally exposed to ochratoxin A. Int Arch Occup Environ Health 2002; 75(6): 381-6.
40. Fischer G, Dott W. Relevance of airborne fungi and their secondary metabolites for environmental, occupational and indoor hygiene. Arch Microbiol 2003; 179: 75-82.
41. Sorenson WG. Fungal spores: hazardous to health? Environ Health Perspect 1999; 107 (Supplement 3): 469-72.
42. Van Emon J, Reed A, Yike I, Vesper S. ELISA measurement of stachylysin in serum to quantify human exposures to the indoor mold Stachybotrys charatarum. J Occup Environ Med 2003; 45: 582-91.
43. Croft W, Jastromski BM, Croft AL, Peters HA. Clinical confirmation of trichothecene mycotoxicosis in patient urine. J Environ Biol 2002; 23(3): 301-20.
44. Johnson P, Sarosi G. Community acquired fungal pneumonias. Semin Resp Infect 1989; 4(1): 56-63.
45. Tierney L, McPhee S, Papadakis M. Current Medical Diagnosis and Treatment. New York: Lange Medical Books, 2003.
46. Nicod L, Pache J, Howarth N. Fungal infections in transplant recipients. Eur Resp J 2001; 17(1): 133-40.
47. Garber G. An overview of fungal infections. Drugs 2001; 61 (Supplement 1): 1-12.
48. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungi at a university hospital. J Infect 1996; 33: 23-32.
49. Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus fungi. Clin Infect Dis 2003; 37(2): 221-9.
50. Denning D. Report on a European Science Foundation Workshop on Invasive Aspergillosis, 21-22 October 1998, University of Manchester, Manchester.
51. Kontoyiannis D, Bodey G. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-72.
52. Denning D. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23(3): 608-15.
53. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systemic review of the literature. Clin Infect Dis 2001; 32(3): 358-66.
54. Fasanen AL. A review: fungal exposure assessment in indoor environments. Indoor Air 2001; 11: 87-98.
55. Dillon HK, Miller JD, Sorenson WG, Douwes J, Jacobs R. Review of methods applicable to the assessment of mold exposure in children. Environ Health Perspect 1999; 107(Supplement 3): 473-80.
56. Tiffany J, Bader H. Detection of Stachybotrys charatarum: the effectiveness of culturable-air sampling and other methods. Environ Health 1999; 2000: 9-11.
57. Gent J, Ren P, Belanger K et al. Levels of household mold associated with respiratory symptoms in the first year of life in a cohort at risk for asthma. Environ Health Perspect 2002; 110(12): A781-6.
58. Dales R, Burnett R, Zwanenburg H. Adverse health effects among adults' exposures to home dampness and molds. Am Rev Resp Dis 1991; 143: 505-9.
59. Ostro B, Lipsett M, Mann J, Braxton-Owens H, White M. Air pollution and exacerbation of asthma in African-American children in Los Angeles. Epidemiology 2001; 12: 200-8.
60. Zock J, Jarvis D, Lucynska G, Sunyer J, Burney P. Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey. J Allergy Clin Immunol 2002; 110(2): 285-92.
61. Williamson I, Martin C, McGill G. Damp housing and asthma: a case control study. Thorax 1997; 52: 229-34.
62. Verhoeff AP, Van Strien RT, Van Wijnen JH, Brunekreef B. Damp housing and household respiratory symptoms: the role of sensitization to dust mites and molds. Am J Epidemiol 1995; 141: 103-10.
63. Strachan DP, Flannigan B, McCabe E, McGarry F. Quantification of airborne moulds in the homes of children with and without wheeze. Thorax 1990; 45: 382-7.
64. Brunekreef B. Damp housing and adult respiratory symptoms. Allergy 1992; 47: 498-502.
65. Waegemaekers M, Van Wageningen N, Brunekreef B, Boleij JS. Respiratory symptoms in damp homes. A pilot study. Allergy 1989; 44: 192-8.
66. Jedrychowski W, Flak E. Separate and combined effects of the indoor and outdoor air quality on chronic respiratory symptoms adjusted for allergy among preadolescent children. Int J Occup Med Environ Health 1998; 11: 19-35.
67. Hu FB, Persky V, Flay BR, Richardson J. An epidemiological study of asthma prevalence and related factors among young adults. J Asthma 1997; 34(1): 67-76.
68. Jaakkola J, Jaakkola N, Ruotsalainen R. Home dampness and molds as determinants of respiratory symptoms and asthma in pre-school children. J Exposure Anal Environ Epidemiol 1993; 3(Supplement 1): 126-42.
69. Slezak J, Persky V, Kviz F, Ramakrishnan V, Byers C. Asthma prevalence and risk factors in selected Head Start sites in Chicago. J Asthma 1998; 35(2): 203-12.
70. Lee YL, Lin YC, Hsiue TR, Hwang BF, Guo YL. Indoor and outdoor environmental exposures, parental atopy and physician diagnosed asthma in Taiwanese schoolchildren. Pediatrics 2003; 112(5): e389-95.
71. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82(3): 233-48.
72. Belanger K, Beckett W, Triche E et al. Symptoms of wheeze and persistent cough in the first year of life: associations with indoor allergens, air contaminants, and maternal history of asthma. Am J Epidemiol 2003; 158: 195-202.
73. Stark PC, Burge HA, Ryan LM, Milton DK, Gold DR. Fungal levels in the home and lower respiratory tract illness in the first year of life. Am J Resp Crit Care Med 2003; 168(2): 232-7.
74. Thorn J, Rylander R. Airways inflammation and glucan in a rowhouse area. Am J Resp Crit Care Med 1998; 157: 1798-803.
75. Chao HJ, Schwartz J, Milton DK, Burge HA. The work environment and workers' health in 4 large office buildings. Environ Health Perspect 2003; 111(9): 1242-8.
76. Pirhonen I, Nevalainen A, Husman T. Home dampness, moulds and their influence on respiratory infections in Finland. Eur Resp J 1996; 9: 2618-22.
77. Koskinen OM, Husman TM, Meklin TM. The relationship between mould and moisture observations in houses and state of health of their occupants. Eur Resp J 1999; 14: 1363-7.
78. Ruotsalainen R, Jaakola N, Jaakola J. Dampness and molds in day-care centers as an occupational health care problem. Int Arch Occup Environ Health 1995; 66: 369-74.
79. Wan GH, Li CS. Dampness and airway inflammation and systemic conditions in office building workers. Arch Environ Health 1999; 54: 58-63.
80. Targonski P, Persky V, Ramakrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol 1995; 95(5 Part 1): 955-61.
81. Neas LM, Dockery DW, Burge H, Koutrakis P, Speizer FE. Fungus spores, air pollutants, and other determinants of peak expiratory flow rates in children. Am J Epidemiol 1996; 143(8): 797-807.
82. Delfino RJ, Zeiger RS, Seltzer JM et al. The effect of outdoor fungal spore concentrations on daily asthma severity. Environ Health Perspect 1997; 105(6): 622-35.
83. Dales RE, Cakmak S, Judek S et al. Influence of outdoor aeroallergens on hospitalization for asthma in Canada. J Allergy Clin Immunol 2004; 113: 303-6.
84. Liccorish K, Novey H, Kozak P, Fairshter R, Wilson A. Role of Alternaria and Penicillium spores in the pathogenesis of asthma. J Allergy Clin Immunol 1985; 76(6): 819-25.
85. O'Halloren M, Yungiger J, Offord K et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991; 324(6): 359-63.
86. Zureik M, Neukirch C, Leynaert B, Laird R, Bousquet J. Sensitization to airborne moulds and severity of asthma: cross sectional study from European Community Respiratory Health Survey. Br Med J 2002; 325(7361): 411-14.
87. Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-1980 (NHANES II). J Allergy Clin Immunol 1992; 90(4 Pt 1): 579-88.
88. Tariq SM, Matthews SM, Stevens M. Hakim EM. Sensitization to Alternaria and Cladosporium by the age of 4 years. Clin Exp Allergy 1996; 26(7): 794-8.
89. Perzanowski MS, Sporik R, Squillance SP et al. Association of sensitization to Alternaria allergens with asthma among school aged children. J Allergy Clin Immunol 1998; 101(5): 626-32.
90. Nelson RP, DiNiccolo R, Fernandez-Caldas E, Seleznick MJ, Lockey R, Good RA. Allergen specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects. J Allergy Clin Immunol 1996; 98(2): 382-8.
91. Lander F, Meyer HW, Norn S. Serum IgE specific to indoor moulds, measured by basophil histamine release, is associated with building-related symptoms in damp buildings. Inflamm Res 2001; 50: 227-31.
92. Schubert M. Medical treatment of allergic fungal sinusitis. Ann Allergy Asthma Immunol 2000; 85(2): 90-101.
93. Greenberger P. Allergic bronchopulmonary aspergillosis, allergic fungal sinusitis and hypersensitivity pneumonitis. Clin Allergy Immunol 2002; 16: 449-68.
94. Ponikau JU, Sherds R, Kern EB. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clinic Proc 1999; 74: 877-84.
95. Lebowitz R, Waltzman M, Jacobs J, Pearlman A, Tierno P. Isolation of fungi by standard laboratory methods in patients with chronic rhinosinusitis. Laryngoscope 2002; 112(12): 2189-91.
96. Rains BM, Mineck CW. Treatment of allergic fungal sinusitis with high-dose itraconazole. Am J Rhinol 2003; 17(1): 1-8.
97. Apostolakos M, Rossmore H, Beckett W. Hypersensitivity pneumonitis from ordinary residential exposures. Environ Health Perspect 2001; 109(9): 979-81.
98. Kita T, Nishi K, Fujimura M et al. A case of hypersensitivity pneumonitis caused by Humicola fuscoatra. Respirology 2003; 8: 95-8.
99. Ando M, Yoshida K, Soda K, Araki S. Specific bronchoalveolar lavage IgA antibody in patients with summer type hypersensitivity pneumonitis induced by Trichosporon cutaneum. Annu Rev Resp Dis 1986; 134: 177-9.
100. Centers for Disease Control (CDC): Pulmonary hemorrhage/hemosiderosis among infants, Cleveland, Ohio, 1993-6. MMWR 1997; 46: 33-5.
101. Montana E, Etzel R, Allan T, Morgan T, Dearborn D. Environmental risk factors associated with pediatric idiopathic pulmonary hemorrhage and hemosiderosis in a Cleveland community. Pediatrics 1997; 99: 117-24.
102. Etzel R, Montana E, Sorenson W et al. Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 1998; 152: 757-62.
103. Vesper S, Dearborn D, Yike I, Sorenson W, Haugland R. Hemolysis, toxicity and randomly amplified polymorphic DNA analysis of Stachybotrys chartarum strains. Appl Environ Microbiol 1999; 65(7): 3175-81.
104. Dearborn D, Smith P, Dahms B et al. Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland. Pediatrics 2002; 110(3): 627-37.
105. Center for Disease Control and Prevention (CDC). Update: Pulmonary hemorrhage/hemosiderosis among infants, Cleveland, Ohio 1993-6. MMWR 2000; 49: 180-184.
106. Etzel T. Stachybotrys. Curr Opin Pediatr 2003; 15(1): 103-6.
107. Vesper S, Magnuson M, Dearborn D, Yike I, Haugland R. Initial characterization of the hemolysin stachylysin from Stachybotrys chartarum. Infect Immun 2001; 69(2): 912-16.
108. Vesper S, Vesper MJ. Stachylysin may be a cause of hemorrhaging in humans exposed to Stachybotrys chartarum. Infect Immun 2002; 70(4): 2065-9.
109. Yike I, Allan T, Sorenson W, Dearborn D. Highly sensitive protein translation assay for trichothecene toxicity in airborne particulates: comparison with cytotoxicity assays. Appl Environ Microbiol 1999; 65(1): 88-94.
110. Johanning E, Biagini R, Hull D, Morey P, Jarvis B, Landsbergis P. Health and immunology study following exposure to toxigenic fungi (Stachybotrys chartarum) in a water-damaged office environment. Int Arch Environ Health 1996; 68: 207-18.
111. Elidemir O, Colasurdo G, Rossmann S, Fan L. Isolation of Stachybotrys from the lung of a child with pulmonary hemosiderosis. Pediatrics 1999; 104(4 Part 1): 964-6.
112. Hooper D. Molecular evaluation for autopsy and clinical tissue in patients. Presented at the 22nd Annual Symposium on Man and His Environment in Health and Disease, Dallas, Texas. 27 June 2004.
113. Vojdani A, Campbell A, Kashanian A, Vojdani E. Antibodies against molds and mycotoxins following exposure to toxigenic fungi in water-damaged building. Arch Environ Health 2003; 58(6): 324-36.
114. Vojdani A, Thrasher J, Madison R, Gray M, Heuser G, Campbell A. Antibodies to molds and satratoxin individuals in a water-damaged building. Arch Environ Health 2003; 58(7): 421-32.
115. Savilahti R, Uitti J, Laippala P, Hussman T, Reiman M. Immunoglobulin G antibodies of children exposed to microorganisms in a water-damaged school. Pediatr Allergy Immunol 2002; 13(6): 438-42.
116. Patovirta RL, Reiman M, Husman T, Haverinen U, Toivola M, Nevalainen A. Mould specific IgG antibodies connected with sinusitis in teachers of a mould damaged school: a 2 year follow up study. Int J Occup Med Environ Health 2003; 16(3): 221-30.
117. Taskinen TM, Laitinen S, Nevalainen A et al. Immunoglobulin G antibodies to moulds in school-children from moisture problem schools. Allergy 2002; 57(1): 9-16.
118. Malkin R, Martinez K, Marinovich V, Wilcox T, Wall D, Biagini R. The relationship between symptoms and IgG and IgE antibodies in an office environment. Environ Res 1998; 76(2): 85-93.
119. Dales R, Miller D, White J, Dulberg C, Lazarovitis A. Incidence of residential fungal contamination on peripheral blood lymphocyte populations in children. Arch Environ Health 1998; 53(3): 190-5.
120. Vojdani A. Health effects and immunotoxicology of toxigenic molds and mycotoxins. Presented at the 21st International Symposium of Man and His Environment in Health and Disease, Dallas, Texas, 20 June 2003.
121. Beijer L, Thorn J, Rylander R. Mould exposure at home relates to inflammatory markers in blood. Eur Resp J 2003; 21(2): 317-22.
122. Bondy G, Pestka J. Immunomodulation by fungal toxins. J Toxicol Environ Health B 2000; 3(2): 109-43.
123. Berek L, Petri IB, Msterhazy A, Teren J, Molnar J. Effects of mycotoxins on human immune functions in vitro. Toxicol In Vitro 2001; 15(1): 25-30.
124. Singer R. Neurotoxicity Guidebook. New York: Van Nostrand Reinold, 1990.
125. Gray M, Kilburn K, Crago R. Molds, mycotoxins and public health: summary of 195 patients treated collaboratively. Presented at the American Public Health Association (APHA) Meeting, Philadelphia, Pennsylvania, 11 November 2002.
126. Crago BR, Gray M, Nelson L, Davis M, Arnold L, Thrasher J. Psychological, neuropsychological and electrocortical effects of mixed mold exposure. Arch Environ Health 2003; 58(8): 452-63.
127. Simon T. Neurotoxicity-mold exposure versus all causes. Presented at the 21st Annual Symposium on Man and His Environment in Health and Disease, Dallas, Texas, 19-22 June 2003.
128. Gordon W, Johanning E, Haddad L. Cognitive impairment associated with exposure to toxigenic fungi. Presented at the 3rd International Conference on Fungi, Mycotoxins and Bioaerosols, Saratoga Springs, New York, 23-25 September 1998. In: Bioaerosols, Fungi and Mycotoxins: Health Effects. Assessments, Prevention and Control. Albany, New York: Eastern New York Center for Environmental and Occupational Health, 1999.
129. Didricksen N. Neurocognitive deficits in individuals exposed to toxigenic molds. Presented at the 21st Annual Symposium on Man and His Environment in Health and Disease, Dallas, Texas, 19-22 June 2003.
130. Baldo JV, Ahmad L, Ruff R. Neuropsychological performance of patients following mold exposure. Appl Neuropsychol 2002; 9(4): 193-202.
131. Anyanwu E, Campbell A, Vojdani A. Neurophysiological effects of chronic indoor environmental toxic mold exposure on children. Sci World J 2003; 3(4): 281-90.
132. Boysen SR, Rozanski EA, Chan DL, Grobe TL, Fallon MJ, Rush J. Tremorgenic mycotoxicosis in four dogs from a single household. J Am Vet Med Assoc 2002; 221(10): 1441-4.
133. Young DL, Villar D, Carson TL, Ierman PM, Moore RA, Bottoff MR. Tremorgenic mycotoxin intoxication with penitrem A and roquefortine in two dogs. J Am Vet Med Assoc 2002; 222(1): 52-3.
134. Naude TW, O'Brien OM, Rundberget T, McGregor AD, Roux C, Flaoyen A. Tremorogenic neuromycotoxicosis in 2 dogs ascribed to ingestion of penitrem A and possibly roquefortine in rice contaminated with Penicillium crustosum. J S Afr Vet Assoc 2002; 73(4): 211-15.
135. Chen JW, Luo YL, Hwang MJ, Peng FC, Ling KH. Territrem B. a tremorgenic mycotoxin that inhibits acetylcholinesterase with a noncovalent yet irreversible binding mechanism. J Biol Chem 1999; 274(49): 34916-23.
136. Krogh P, Hald B, Pedersen J. Occurrence of ochratoxin A and citrinin in cereals associated with mycotoxic porcine nephropathy. Acta Path Micro Scand 1973; 81 Sect B: 689-95.
137. Castegnaro M, Plestina R, Dirheimer O, Chernosemsky IN, Barsch H. Mycotoxins, endemic nephropathy and urinary tract tumors. IARC Sci Pub 1991; 115: 1-340.
138. Kristensen P, Irgens L, Andersen A, Bye AS, Sundheim L. Gestational age, birth weight, and perinatal death among births to Norwegian farmers, 1967-1991. Am J Epidemiol 1997; 146: 329-38.
139. Kristensen P, Andersen A, Irgens L. Hormone-dependent cancer and adverse reproductive outcomes in farmers families-effects of climatic conditions favoring fungal growth in grain. Scand J Work Health 2000; 26(4): 331-7.
140. Diekman M, Green M. Mycotoxins and reproduction in domestic livestock. J Anim Sci 1992; 70: 1615-27.
141. Cotran RS. Robbins Pathologic Basis of Disease, 5th edn. New York: WB Saunders, 1994, p. 914.
142. Cheta D. Animal models of type 1 (insulin-dependent) diabetes mellitus. J Pediatr Endocrinol Metab 1998; 11(1): 11-19.
143. Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol Oncol 2004; 26(2): 81-90.
144. Eggleston PA. Environmental control for fungal allergen exposure. Curr Allergy Asthma Rep 2003; 3(5): 424-9.
145. Heuser G, Axelrod P, Heuser S. Defining chemical injury: a diagnostic protocol and profile of chemically injured civilians, industrial workers and Gulf War veterans. Int Perspect Public Health 2002; 13: 1-16.
146. Marshall L, Weir E, Abelsohn A, Sanborn MD. Identifying and managing adverse environmental effects: 1) taking an exposure history. Can Med Assoc J 2002; 166(8): 1049-55.
147. Dales RE, Miller D, McMullen E. Indoor air quality and health: validity and determinants of reported home dampness and molds. Int J Epidemiol 1997; 26: 120-4.
148. Macher J (ed.) Bioaerosols: Assessment and Control. American Conference of Governmental and Industrial Hygienists (ACGIH), Cincinnati, Ohio, 1999.
149. Portnoy JM, Barnes CS, Kennedy K. Sampling for indoor fungi. J Allergy Clin Immunol 2004; 113: 189-98.
150. Institute of Medicine Committee on the Health Effects of Indoor Allergens: Engineering Control Strategies. Allergens: Assessing and Controlling Adverse Health Effects. Engineering Control Strategies. Washington, DC: National Academy Press, 1993, 206-32.
151. Institute for Inspection, Cleaning and Restoration. IICRC S520 Standard and reference guide for professional mold remediation. Vancouver, Washington: IICRC Press, 2003.
152. Higgins BG, Francis HC, Yates G et al. Environmental exposure to air pollution and allergens and peak flow changes. Eur Resp J 2000; 16(1): 61-6.
153. Thorn J, Brisman J, Toren K. Adult-onset asthma is associated with self-reported mold or environmental tobacco smoke in the home. Allergy 2001; 56: 287-92.
154. Chen WY, Tseng HI, Wu MT et al. Synergistic effect of multiple indoor allergen sources on atopic symptoms in primary school children. Environ Res 2003; 93(1): 1-8.
155. Skoner DP. Viral infection and allergy: lower airway. Allergy Asthma Proc 2002; 23(4): 229-32.
156. Fireman P. Virus-provoked rhinitis in patients who have allergies. Allergy Asthma Proc 2002; 23(2): 99-102.
157. Hirsch D, Hirsch R, Kalbfleish S. Effect of central air-conditioning and meterological factors on indoor spore counts. J Allergy Clin Immunol 1978; 62(1): 22-6.
158. Sheretz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial Aspergillus infections. Am J Med 1987; 83(4): 709-18.
159. Panackal A, Dahlman A, Keil K et al. Outbreak of invasive aspergillosis among renal transplant patients. Transplantation 2003; 75(7): 1050-3.
160. Oren I, Haddad N, Finkelstein R, Rowe J. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66(4): 257-62.
161. Loo V, Betrand C, Dixon C et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17(6): 360-4.
162. Iwen P, Davis J, Reed EC, Winfield BA, Hinrichs SH. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with outbreak of invasive aspergillosis. Infect Control Hosp Epidemiol 1994; 15(5): 303-6.
163. Hahn T, Cummings K, Michalek AM, Lipman B, Segel B, McCarthy P. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002; 23(9): 525-31.
164. Cornet M, Levy V, Fleury L et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20(7): 508-13.
165. Withington S, Chambers ST, Beard ME et al. Invasive aspergillosis in severely neutropenic patients over 18 years: impact of intranasal amphotericin B and HEPA filtration. J Hosp Infect 1998; 38(1): 11-18.
166. Annaisie EJ, Stratton SL, Dignani MC et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3 year prospective study. Clin Infect Dis 2002; 34(6): 780-9.
167. Annaisie EJ, Stratton SL, Dignani MC et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002; 35(8): E86-8.
168. Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Invest Allergol Clin Immunol 1996; 6(1): 55-62.
169. Helbling A, Reimers A. Immunotherapy in fungal allergy. Curr Allergy Asthma Rep 2003; 3(5): 447-53.
170. Galvano F, Piva A, Ritieni A, Galvano G. Dietary strategies to counteract the effects of mycotoxins: a review. J Food Protect 2001; 64(1): 120-31.
171. Atroshi F, Rizzo A, Westermarck, Ali-Vehmas T. Antioxidant nutrients and mycotoxins. Toxicology 2002; 180(2): 151-67.